Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
about
Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancerStructure-antiproliferative activity studies on l-proline- and homoproline-4-N-pyrrolidine-3-thiosemicarbazone hybrids and their nickel(ii), palladium(ii) and copper(ii) complexes.A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cellsConserved electron donor complex Dre2-Tah18 is required for ribonucleotide reductase metallocofactor assembly and DNA synthesisRibonucleotide reductase metallocofactor: assembly, maintenance and inhibition.Stimulation of proliferation in the colorectal mucosa by gastrin precursors is blocked by desferrioxamineDetoxifying carcinogenic polyhalogenated quinones by hydroxamic acids via an unusual double Lossen rearrangement mechanism.Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunitiesComplex N-acetylation of triethylenetetramine.Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved PharmacokineticsIn Vitro Antileukemic Activity of Xanthosoma sagittifolium (Taioba) Leaf Extract.Investigation of in vivo diferric tyrosyl radical formation in Saccharomyces cerevisiae Rnr2 protein: requirement of Rnr4 and contribution of Grx3/4 AND Dre2 proteinsDeferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.Mechanistic studies of semicarbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species.Targeting cancer by binding iron: Dissecting cellular signaling pathwaysMechanistic basis for overcoming platinum resistance using copper chelating agents.Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine.Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.Clawing back: broadening the notion of metal chelators in medicineIron-independent phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycleImpact of Stepwise NH2-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance CircumventionSynthetic and natural iron chelators: therapeutic potential and clinical useIdentification of compounds selectively killing multidrug-resistant cancer cellsIron chelators target both proliferating and quiescent cancer cells.The association of serum vascular endothelial growth factor and ferritin in diabetic microvascular disease.Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling.Copper complexes as therapeutic agents.Siderophore-based detection of Fe(III) and microbial pathogens.Insights into the binding of thiosemicarbazone derivatives with human serum albumin: spectroscopy and molecular modelling studies.A Powerful Mitochondria-Targeted Iron Chelator Affords High Photoprotection against Solar Ultraviolet A Radiation.Reviving the guardian of the genome: Small molecule activators of p53.Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex.The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
P2860
Q26800059-FB659430-D324-4F52-9C8D-6B9A8922A094Q31119195-2AEF8DF0-AF4B-44E1-8DFE-7CED1876F10EQ33382443-B1220B15-D368-4B72-820D-1EA7C34785D3Q33534491-ADECD78D-9680-46BB-B942-6CB3076C6E58Q33674147-41E1089C-A59E-46C8-93CD-63CA32A1CE34Q33699869-67597230-B21F-4C28-A929-B3746D933191Q33994802-4AF40283-5E15-4834-BD39-CD6AE67B3D12Q34375933-DF42D0B2-CC64-4C2E-80DE-B6E2F5C7DAA9Q34458507-F60B7EC5-0F7E-44F7-8A9C-275FBFB7B201Q34459006-C2DF0B2A-0019-4C89-BC9F-87833352F361Q34610646-26679DAA-1478-4580-9DFA-FE60092C83E9Q34615592-2081F72C-68DF-4FC1-BB55-1E79EC724732Q35034547-48CCE0B1-0BEE-4CFD-B889-54BB690D84C3Q35579534-4F05B881-7C69-4387-A116-6793B77C026EQ35598226-2ECE5707-8C93-41E7-9D4F-1E8B17E3DCD9Q35768770-CC2AA191-A4C9-4841-BB00-9CEBBCFA74F9Q35842180-2F6F6A74-18EE-42AA-A09B-4BB11744C339Q36119319-50BDC566-A298-4E25-A548-001F573821CBQ36318799-B58783A3-49CA-4749-8025-D2F123555A43Q36326247-4A93A71B-9237-458E-9C60-31B63EB1C084Q36392693-D825EC2A-DF15-43F0-B86C-C9464667F4DCQ36568904-FE69FAB9-4E5F-4A4A-A118-E443E5FA9F40Q36666495-1C7611F3-8FA0-460D-A349-82204016738DQ36681744-1281A565-05D4-452A-A2E1-727A9390629BQ36791445-1F30A100-3B5A-47F3-8949-D35720E9EA75Q36855783-F4F665C1-27CD-4741-B991-CC9A06EE8901Q37138681-2A418850-7F97-45F7-B68D-228F356B4730Q37290073-EA52703D-A856-42C4-BE1F-4C66114101DDQ37440253-F1DD8EB8-7FBE-432B-BFE8-ACF48712F6B5Q37479772-CDCEECB0-4D6D-4E16-8D96-2136BBAB8F02Q37634929-E9F3BC7E-4EBF-4426-89F7-EE2F541DB671Q37708984-FA13CB22-3BB3-4825-B1B9-F284183341D8Q37970312-96C032F9-4E33-49E8-97A8-675C95F12D70Q38031391-2D7862CB-B793-4525-BA23-D5BACE505B66Q38386795-CA8DB939-916B-4F64-AFA6-954BFF27BE90Q38775707-8AE22ECE-3395-4EA0-99F3-D573D4CEDC59Q39205536-870E2476-AC23-4393-9917-ED9FBC25D5E4Q39466509-EC9740EB-F880-43CC-A54B-5FCB8985B01EQ39753374-FFD94287-96D3-43D1-B31E-37D775D5DD50Q39870984-59B9E191-4292-49E0-B591-E68CB583851E
P2860
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
@ast
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
@en
type
label
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
@ast
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
@en
prefLabel
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
@ast
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
@en
P50
P1476
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond
@en
P2093
Jacky Wong
P304
P356
10.1158/1078-0432.CCR-06-1954
P407
P577
2006-12-01T00:00:00Z